Psoriatic Arthritis
Conference Coverage
Ixekizumab helps PsA patients who failed a TNFi
MADRID – Ixekizumab appears to be a good second-line choice for TNFi-unresponsive patients.
News from the FDA/CDC
First IL-23 blocker, guselkumab, earns FDA approval for psoriasis
The approved indication is for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Conference Coverage
Comorbidities in psoriatic arthritis flag worse prognosis
MADRID - Focus on comorbidities to improve treatment.
News
FDA approves abatacept for adults with psoriatic arthritis
The approval expands the approved indications of abatacept to three autoimmune diseases.
Conference Coverage
Early phase III data positive for adalimumab biosimilar, for both psoriasis and PsA
Response curves were nearly identical for adalimumab and the biosimilar
Conference Coverage
Apremilast eases PsA symptoms in patients who are naive to biologics
MADRID - Response to the drug increased over time.
Conference Coverage
Panel revises spondyloarthritis treat-to-target recommendations
MADRID – Nearly half of the recommendations now backed by evidence.
Conference Coverage
Ustekinumab trumps TNF-blockade for enthesitis in patients with psoriatic arthritis
After 6 months, 71% of those taking ustekinumab showed total enthesitis clearance.
Conference Coverage
VIDEO: Guselkumab bests placebo in psoriatic arthritis
MADRID – The IL-23 blocker bested placebo on ACR 20 response and each secondary endpoint.
Conference Coverage
Pain often persists despite biologic treatment in PsA
MADRID – Psoriatic arthritis patients may have more than just inflammatory pain symptoms.
From the Journals
Experts endorse routine screening for pediatric psoriasis comorbidities
Here’s what to look for when screening for comorbidities in pediatric psoriasis patients.